Effect of zinc supplementation on microalbuminuria in patients with type 2 diabetes: a double blind, randomized, placebo-controlled, cross-over trial.
OBJECTIVE
Oxidative stress can contribute to microvascular complications in diabetes. A decisive event associated with this condition may be the decrease in the synthesis of zinc-containing antioxidant enzymes such as superoxide dismutase and glutathione peroxidase. This consideration led us to investigate the effect of zinc supplementation versus placebo on microalbuminuria in diabetic patients in a randomized double blind clinical trial.


METHODS
Fifty diabetic patients with microalbuminuria were enrolled. Fasting plasma glucose, HbA1c, lipid profiles, plasma zinc levels and random urine for albumin and creatinine were measured. Patients randomly received 30 mg elemental zinc (group 1) or placebo (group 2) for 3 months. After a 4 week wash-out period, the groups were crossed over (i.e. the zinc group were given placebo, and the placebo group were given zinc) and the protocol was repeated.


RESULTS
From an initial number of 50 selected patients (25 in each of two groups), 39 patients (21 in group 1 and 18 in group 2) completed the study. In group 1, after zinc supplementation, urinary albumin excretion decreased significantly from 86.5 +/- 57 to 75 +/- 71 mg/g (p = 0.01). After placebo, patients in group 1 showed no significant reduction in microalbuminuria (85 +/- 72 mg/g to 83 +/- 63 mg/g creatinine). In group 2, no change in albumin excretion was observed after placebo treatment (90.5 +/- 63 mg/g to 90 +/- 60 mg/g creatinine). After zinc supplementation, a significant reduction was observed in albumin excretion, from 90 +/- 60 mg/g to 85 +/- 57 mg/g creatinine (p = 0.003).


CONCLUSIONS
Zinc supplementation reduced albumin excretion in microalbuminuric type 2diabetic patients. This outcome may be due to the antioxidant effect of zinc.
Parham
Mahmoud
M
Isfahan Endocrine and Metabolism Research Center, Sedigheh Tahereh Research Complex, Isfahan University of Medical Sciences, Isfahan, Iran.
Amini
Massoud
M
Aminorroaya
Ashraf
A
Heidarian
Esfandiar
E
J Hypertens. 2002 Jun;20(6):1045-6
12023662
Rev Diabet Stud. 2007 Winter;4(4):242-8
18338078
Diabetes Care. 2007 Apr;30(4):989-92
17392559
Diabetes Care. 2005 Oct;28(10):2458-64
16186280
Int J Vitam Nutr Res. 1999 May;69(3):206-12
10389029
Clin Chem. 1972 Jun;18(6):499-502
4337382
J Hypertens. 2005 Apr;23(4):697-701
15775768
Scand J Clin Lab Invest. 1965;17(4):381-7
5838275
Nephrol Dial Transplant. 1996 Mar;11(3):449-56
8671814
Nephron. 1976;16(1):31-41
1244564
J Int Fed Clin Chem. 1998 Mar;10(1):21-3
10181011
Nephron. 1999;83(4):361-2
10575300
Hypertension. 1997 Jan;29(1 Pt 2):188-93
9039100
J Am Coll Nutr. 2003 Aug;22(4):316-21
12897047
Curr Hypertens Rep. 2005 Oct;7(5):379-84
16157083
Lancet. 1995 Oct 21;346(8982):1080-4
7564792
Diabetes Res Clin Pract. 1998 Nov;42(2):117-21
9886748
J Pineal Res. 2006 Sep;41(2):189-93
16879326
Diabetologia. 1993 Oct;36(10):1051-6
8243854
Ann Biol Clin (Paris). 1986;44(1):77-87
3706837
J Trace Elem Med Biol. 2006;20(1):3-18
16632171
Diabetes Care. 1996 Mar;19(3):257-67
8742574
Saudi Med J. 2006 Mar;27(3):344-50
16532095
J Am Coll Cardiol. 1996 Mar 1;27(3):567-74
8606266
Clin Sci (Lond). 1993 Dec;85(6):687-93
8287660